Fusobacterium nucleatum and its associated systemic diseases: epidemiologic studies and possible mechanisms
- PMID: 36407281
- PMCID: PMC9673791
- DOI: 10.1080/20002297.2022.2145729
Fusobacterium nucleatum and its associated systemic diseases: epidemiologic studies and possible mechanisms
Abstract
Background: Fusobacterium nucleatum (F. nucleatum) is an anaerobic oral commensal and the major coaggregation bridge organism linking early and late colonisers. In recent years, a large number of studies suggest that F. nucleatum is closely related to the development of various systemic diseases, such as cardiovascular diseases, adverse pregnancy outcomes, inflammatory bowel diseases, cancer, Alzheimer's disease, respiratory infection, rheumatoid arthritis, etc.
Objective: To review the effect of F. nucleatum on systemic diseases and its possible pathogenesis and to open new avenues for prevention and treatment of F. nucleatum-associated systemic diseases.
Design: The research included every article published up to July 2022 featuring the keywords 'Systemic diseases' OR 'Atherosclerotic cardiovascular diseases' OR 'Atherosclerosis' OR 'Adverse pregnancy outcomes' OR 'Inflammatory bowel disease' OR 'Ulcerative colitis' OR 'Crohn's disease' OR 'Cancers' OR 'Oral squamous cell carcinomas' OR 'Gastrointestinal cancers' OR 'Colorectal cancer' OR 'Breast cancer' OR 'Genitourinary cancers' OR 'Alzheimer's disease ' OR 'Rheumatoid arthritis' OR 'Respiratory diseases' AND 'Fusobacterium nucleatum' OR 'Periodontal pathogen' OR 'Oral microbiota' OR 'Porphyromonas gingivalis' and was conducted in the major medical databases.
Results: F. nucleatum can induce immune response and inflammation in the body through direct or indirect pathways, and thus affect the occurrence and development of systemic diseases. Only by continuing to investigate the pathogenic lifestyles of F. nucleatum will we discover the divergent pathways that may be leveraged for diagnostic, preventive and therapeutic purposes.
Keywords: FadA; Fusobacterium nucleatum; microbiome; periodontal disease; systemic diseases.
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures


Similar articles
-
Fusobacterium nucleatum: a commensal-turned pathogen.Curr Opin Microbiol. 2015 Feb;23:141-7. doi: 10.1016/j.mib.2014.11.013. Epub 2015 Jan 8. Curr Opin Microbiol. 2015. PMID: 25576662 Free PMC article. Review.
-
The Role of Fusobacterium nucleatum in Oral and Colorectal Carcinogenesis.Microorganisms. 2023 Sep 20;11(9):2358. doi: 10.3390/microorganisms11092358. Microorganisms. 2023. PMID: 37764202 Free PMC article. Review.
-
Oral Fusobacterium nucleatum exacerbates ulcerative colitis via the oral-gut axis: mechanisms and therapeutic implications.Front Cell Infect Microbiol. 2025 Apr 7;15:1564169. doi: 10.3389/fcimb.2025.1564169. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40260115 Free PMC article. Review.
-
Fecal Fusobacterium nucleatum harbored virulence gene fadA are associated with ulcerative colitis and clinical outcomes.Microb Pathog. 2021 Aug;157:104964. doi: 10.1016/j.micpath.2021.104964. Epub 2021 May 20. Microb Pathog. 2021. PMID: 34022363
-
Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers.Cells. 2024 Apr 20;13(8):717. doi: 10.3390/cells13080717. Cells. 2024. PMID: 38667331 Free PMC article. Review.
Cited by
-
Targeted elimination of Fusobacterium nucleatum alleviates periodontitis.J Oral Microbiol. 2024 Aug 12;16(1):2388900. doi: 10.1080/20002297.2024.2388900. eCollection 2024. J Oral Microbiol. 2024. PMID: 39139835 Free PMC article.
-
The Roles of Periodontal Bacteria in Atherosclerosis.Int J Mol Sci. 2023 Aug 16;24(16):12861. doi: 10.3390/ijms241612861. Int J Mol Sci. 2023. PMID: 37629042 Free PMC article. Review.
-
Intratumoral Fusobacterium nucleatum in Pancreatic Cancer: Current and Future Perspectives.Pathogens. 2024 Dec 26;14(1):2. doi: 10.3390/pathogens14010002. Pathogens. 2024. PMID: 39860963 Free PMC article. Review.
-
Addressing controversy in Fusobacterium nomenclature: what exactly does "F. nucleatum" refer to?Gut Microbes. 2025 Dec;17(1):2514797. doi: 10.1080/19490976.2025.2514797. Epub 2025 Jun 4. Gut Microbes. 2025. PMID: 40464118 Free PMC article.
-
The Potential Role and Effective Components of Sanyeqing as the Potential Therapeutic Candidates for IBD and CRC.Onco Targets Ther. 2025 Jul 7;18:779-788. doi: 10.2147/OTT.S516341. eCollection 2025. Onco Targets Ther. 2025. PMID: 40655939 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources